Effect of PD-1 inhibitor combined with concurrent chemoradiotherapy in the treatment of locally advanced unresectable esophageal cancer
Objective To investigate the efficacy and safety of programmed cell death protein-1(PD-1)inhibitor combined with concurrent chemoradiotherapy in the treatment of patients with locally advanced unresectable esophageal cancer.Methods A total of 42 patients with locally advanced unresectable esophageal cancer treated in Xinyi People's Hospital were selected as the research objects,and the patients were randomly divided into control group and observation group,with 21 cases in each group.The control group was treated with radical radiotherapy+paclitaxel combined with cisplatin chemotherapy,and the observation group was treated with PD-1 inhibitor on this basis.The therapeutic effect between the two groups were compared.Results The objective response rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group(P＜0.05).There were no significant differences in the incidence of radiation esophagitis,radiation pneumonia,agranulocytosis and gastrointestinal reaction between the two groups(P＞0.05).After treatment,the scores of body pain,health status,mental state and physiological function in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion PD-1 inhibitor combined with concurrent chemoradiotherapy in the treatment of locally advanced unresectable esophageal cancer can significantly improve the clinical effect and quality of life,and does not increase the incidence of adverse reactions.
programmed cell death protein-1concurrent chemoradiotherapyesophageal cancer
万方数据
维普
